Zimmer Biomet Holdings, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Zimmer Biomet Holdings, Inc. stock analysis ZBH overview
Bullish +75

Zimmer Biomet discloses executive pay and double-digit increase for its median employee

📊 Zimmer Biomet reported $8.23 billion in 2025 revenue, a 7% increase from the prior year, driven partly by acquisitions including Paragon 28 and Monogram Technologies.

💰 CEO Ivan Tornos received $16.1 million in total compensation for 2025, representing a 7% increase over the previous year's $15 million.

🎁 Tornos' pay package consisted of $1.3 million in salary, $12 million in stock awards, $2.4 million in performance bonuses, and over $400k in other perks including corporate aircraft usage.

👥 SVP Jehanzeb Noor was paid $7.8 million for 2025, a figure converted from Swiss Francs to USD using an average exchange rate of 1.2043.

🚀 Noor joined in March after previously leading Trivium's Europe, Africa, and Asia regions, receiving significant cash bonuses to replace forfeited payments from his previous role.

💵 CFO Suketu Upadhyay earned $6.2 million in 2025 but departed the company on April 28, 2026, to join biotech firm Incyte as its new CFO.

🔄 Paul Stellato was promoted to interim CFO while the board searches for a permanent successor following Upadhyay's departure.

🌎 Global Business and Americas President Kevin Thornal received $6.2 million in compensation, including $5.3 million in stock awards, after joining from Globus Medical-owned Nervo Corp.

⚖️ EMEA President Wilfred van Zuilen saw a 17% pay rise to $4.1 million for 2025, with his compensation package including a corporate apartment and car allowance valued at over $100k combined.

📈 The company's median employee experienced a double-digit increase in pay, aligning with broader disclosures required by the U.S. SEC for top executives.

🏆 Zimmer Biomet ranks as the 18th-largest medical device company globally based on 2024 revenue of $7.68 billion according to Medtech Big 100 data.

🤝 Strategic acquisitions in 2025 included Paragon 28 for foot and ankle expansion and Monogram Technologies to bolster the robotics portfolio with AI capabilities.

🧠 Executives like Noor and Thornal bring significant international experience, having previously led major regions or managed independent medical device firms before joining.

💸 A substantial portion of executive compensation at Zimmer Biomet is tied to stock awards, reinforcing alignment between leadership interests and long-term shareholder value.

✈️ Perks such as corporate aircraft usage, deferred compensation matching, and tax assistance contribute significantly to the total "other compensation" categories for senior leaders.

Bullish Signals
  • Zimmer Biomet reported 2025 revenue of $8.23 billion, representing a strong 7% year-over-year growth from the prior year.
  • The company successfully expanded its footprint with the $1.3 billion acquisition of Paragon 28 in April 2025 to enhance its foot and ankle segment.
  • Zimmer Biomet further strengthened its portfolio by acquiring AI-driven robotics company Monogram Technologies in 2025.
  • CEO Ivan Tornos received a total compensation package of $16.1 million for 2025, a 7% increase from the previous year, signaling confidence in performance.
  • SVP and Chief Strategy Officer Jehanzeb Noor was recruited with an attractive package including a one-time $1.1 million cash bonus to help retain top talent.
  • EMEA Group President Wilfred van Zuilen saw a significant 17% increase in his total compensation for 2025 compared to the prior year.
  • The company is ranked as the world's 18th-largest medical device company based on 2024 revenue, highlighting its strong market position.
Risk Factors
  • CEO Ivan Tornos received $1.3 million in salary and $12 million in stock awards, raising questions about whether executive compensation is aligned more with shareholder dilution than performance given the company's reported revenue increase was only 7%.
  • The departure of former CFO Suketu Upadhyay on April 28, 2026, to join biotech rival Incyte represents a significant retention risk and potential knowledge drain as Zimmer Biomet searches for a permanent successor, currently led by an interim CFO.
  • Executive compensation packages include substantial non-business perks such as corporate aircraft usage totaling $178,842 for CEO Ivan Tornos and $38,857 for former CFO Suketu Upadhyay, which may be viewed skeptically by investors focusing on operational efficiency.
  • Zimmer Biomet paid Wilfred van Zuilen a $67,449 corporate paid apartment allowance, highlighting significant overhead spending that could detract from R&D or growth investments in the competitive medical device sector.
  • The company acquired two entities in 2025, Paragon 28 for $1.3 billion and AI-driven robotics company Monogram Technologies, creating integration risks and potential goodwill impairment concerns if these acquisitions do not deliver expected synergies quickly enough.
Full Analysis
Zimmer Biomet has released its executive compensation disclosures for fiscal year 2025, highlighting a double-digit increase in median employee pay alongside specific packages for top leadership. The world’s 18th-largest medical device company reported revenue of $8.23 billion in 2025, representing a 7% year-over-year increase from 2024. This growth was partially attributed to the April 2025 acquisition of Paragon 28 for $1.3 billion and the acquisition of AI-driven robotics firm Monogram Technologies to expand its product portfolio. CEO Ivan Tornos received $16.1 million in total compensation, a 7% increase from the previous year’s $15 million. His package consisted of a $1.3 million salary, $12 million in stock awards, a $2.4 million cash performance bonus, and approximately $404,000 in other benefits including corporate aircraft usage and deferred compensation matching. Jehanzeb Noor, SVP and Chief Strategy officer who joined in March, received $7.8 million, which included a one-time $1.1 million cash bonus to replace forfeited payments from his previous role at Trivium, along with $5.1 million in stock awards and a car allowance of roughly $27,000. Former CFO Suketu Upadhyay departed the company on April 28, 2026, to join Incyte as CFO, having earned $6.2 million in total compensation for 2025 before his exit. He was succeeded by Paul Stellato, who is currently serving as interim CFO and Controller. Kevin Thornal, President of Global Business and the Americas Group, earned $6.2 million with a heavy emphasis on equity ($5.3 million in stock awards) after joining in July. Wilfred van Zuilen, EMEA Group President, saw his total compensation rise 17% to $4.1 million, driven by significant pension value changes and benefits such as a corporate-paid apartment and car allowance. All figures reflect disclosures required by the SEC and include currency conversions where applicable.